Loading...

Avalo Therapeutics, Inc.

AVTX•NASDAQ
Healthcare
Biotechnology
$22.87
$1.06(4.86%)
U.S. Market opens in 4h 49m

Avalo Therapeutics, Inc. (AVTX) Stock Overview

Explore Avalo Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap258.3M
P/E Ratio-3.89
EPS (TTM)$-5.87
ROE-0.78%
Fundamental Analysis

AI Price Forecasts

1 Month$17.86
3 Months$19.34
1 Year Target$0.00

AVTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Avalo Therapeutics, Inc. (AVTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 78.42, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.89 and a market capitalization of 258.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
4.86%
5-Day Change
69.03%
1-Month Change
43.66%
3-Month Change
61.17%
6-Month Change
51.96%
Year-to-Date (YTD) Change
25.94%
1-Year Change
413.93%
3-Year Change
-96.39%
5-Year Change
-99.71%
All-Time (Max) Change
-99.88%

Contact Information

https://www.avalotx.com
410 522 8707
540 Gaither Road, Rockville, MD, 20850

Company Facts

23 Employees
IPO DateOct 14, 2015
CountryUS
Actively Trading

Frequently Asked Questions